Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc announced a strategic collaboration agreement with Latch Medical Limited, together with an agreed-in-principle strategic equity investment, to develop biosensor-guided precision drug delivery solutions that combine its AI-native CGM+ wearable biosensor platform with Latch Medical’s Pharma Latch microneedle-based intradermal delivery technology.
The partners plan to use real-time metabolic data from CGM+ to help guide and optimize therapeutic delivery for diabetes, obesity and other metabolic conditions, supporting Trinity Biotech’s goal of an integrated metabolic health platform linking continuous sensing, AI-driven insights and precision delivery. Trinity Biotech’s largest financial investor, Perceptive Advisors, is supporting the planned investment, and management views the convergence of these technologies as a significant long-term opportunity in large metabolic disease markets.
Trinity Biotech plc plans to change the ratio of its American depositary shares so that one ADS will represent six hundred Class A ordinary shares instead of twenty. For ADS holders, this functions as a one-for-thirty reverse ADS split. The ADS ratio change is expected to be reflected in trading on the Nasdaq Global Market at the open on July 24, 2026 U.S. Eastern Time.
ADS holders must mandatorily surrender every thirty existing ADSs to The Bank of New York Mellon to receive one new ADS, with no fractional ADSs issued. Fractional entitlements will be aggregated, sold by the depositary, and net cash proceeds distributed to holders. The change does not affect the underlying Class A ordinary shares. The action is intended to support compliance with the $1.00 Nasdaq minimum bid price requirement and to appeal to investors who avoid securities trading below $5.00, and the ADS price is expected to increase proportionally, although no specific price outcome is assured.
Trinity Biotech plc reported new clinical trial results for its next-generation CGM+ wearable biosensor platform. The study analyzed about 5,000 hours of device wear data from insulin-dependent people with diabetes in a pre-pivotal trial completed in the second quarter of 2026.
The data show that CGM+ can distinguish nocturnal compression-related false low glucose readings from true blood glucose lows by combining glucose measurements with additional physiological signals and AI-driven analytics. This capability targets a common limitation of conventional continuous glucose monitoring systems.
The company highlights this as validation of its multi-sensor platform strategy and a way to improve user experience by reducing false alarms, sleep disruption and avoidable glucose variability, while providing automated insulin delivery partners with richer, contextual data within a global CGM market estimated at $15 billion.
Trinity Biotech filed a Form 6-K to highlight that its new subsidiary, Trinovium, has secured Silver Membership in the Open Compute Project, a major global community that shapes next‑generation data center infrastructure.
The company sees this as an important step in launching Trinovium’s high‑performance liquid cooling solutions into the AI data center ecosystem. Membership is expected to support product development, accreditation to hyperscale specifications, and access to large data center customers, leveraging Trinity Biotech’s fluid science and manufacturing capabilities in a data center liquid cooling market projected to grow strongly over the coming years.
Trinity Biotech plc has terminated its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global. This agreement had provided an equity line of credit facility. The company states it no longer intends to use the facility, and that ending it reflects its current financing strategy.
Trinity Biotech plc updates a prospectus supplement registering the resale by selling shareholders of up to 33,752,429 ADSs, representing 675,048,580 Ordinary Shares. The offering is a secondary resale by holders and does not state proceeds to the company.
The supplement incorporates a Form 6-K announcing the launch of Trinovium, a new subsidiary targeting the AI data centre liquid cooling market, and discloses a June 22, 2026 ADS last reported sale price of $0.582.
Trinity Biotech plc has formed a new subsidiary, Trinovium, to apply its healthcare‑grade fluid manufacturing and analytical expertise to liquid cooling solutions for AI and high‑performance computing data centers. The business targets reliability and performance issues as data centers shift from air to liquid cooling.
The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, a 31.5% CAGR, and Trinovium plans to use Trinity’s existing US and EU capacity to enter this market in a capital‑efficient way. It is developing direct‑to‑chip cooling fluids and a monitoring and analytics platform to create high‑margin recurring revenue, while Trinity continues to commercialize its core diagnostic and diabetes management products.
Trinity Biotech plc files a prospectus supplement registering a secondary resale of up to 33,752,429 ADSs, representing 675,048,580 ordinary shares, for sale by selling shareholders from time to time. The resale is by the Selling Shareholders and not an issuer primary offering.
The supplement incorporates a Form 6-K disclosing Q1 2026 results and commercial updates: Q1 2026 revenue $10.8M (up 43% year-on-year), gross margin 35.4% (up from 25.2%), net loss $4.4M, and adjusted EBITDA -$1.1M. The company announced purchase orders for over 2 million TrinScreen HIV tests scheduled for fulfillment in Q3 2026. The ADS last reported sale price on June 17, 2026 was $0.5799.
Trinity Biotech plc reported a strong Q1 2026 recovery, with revenue rising 43% to $10.8m from $7.6m in Q1 2025, driven by rapid HIV and haemoglobin products. Rapid HIV sales reached $3.7m, including TrinScreen HIV revenue of $2.3m versus $0.4m a year earlier.
Gross margin improved from 25.2% to 35.4%, lifting gross profit to $3.8m from $1.9m. The net loss narrowed to $4.4m from $8.8m, and adjusted EBITDA improved to negative $1.1m from negative $4.0m, reflecting benefits from its Comprehensive Transformation Plan.
The company also received purchase orders for over 2 million TrinScreen HIV tests, scheduled for Q3 2026, which are expected to support 2026 revenue and profitability goals and further validate demand for rapid HIV diagnostics in global health markets.
Trinity Biotech plc filed a prospectus registering for resale up to 33,752,429 ADSs (each ADS = 20 ordinary shares) related to a Standby Equity Purchase Agreement with YA II PN, LTD., under which the company may sell up to $25 million of ADSs to the investor.
The prospectus states the resale is by the Selling Securityholder and that the company will not receive proceeds from resales; the company may, at its election, sell ADSs to the investor under the Purchase Agreement and could receive up to $25 million in aggregate gross proceeds if it elects to sell ADSs into the commitment.